Clindagel is a drug owned by Bausch Health Us Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 03, 2020. Details of Clindagel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6387383 | Topical low-viscosity gel composition |
Aug, 2020
(4 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Clindagel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clindagel's family patents as well as insights into ongoing legal events on those patents.
Clindagel's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Clindagel's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 03, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Clindagel Generic API suppliers:
Clindamycin Phosphate is the generic name for the brand Clindagel. 42 different companies have already filed for the generic of Clindagel, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clindagel's generic
Alternative Brands for Clindagel
Clindagel which is used for treating acne vulgaris., has several other brand drugs in the same treatment category and using the same active ingredient (Clindamycin Phosphate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clindamycin Phosphate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Almirall |
| ||||
| Bausch |
| ||||
| Norvium Bioscience |
| ||||
| Organon Llc |
| ||||
| Padagis Us |
| ||||
| Pfizer |
| ||||
| Stiefel |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clindamycin Phosphate, Clindagel's active ingredient. Check the complete list of approved generic manufacturers for Clindagel
About Clindagel
Clindagel is a drug owned by Bausch Health Us Llc. It is used for treating acne vulgaris. Clindagel uses Clindamycin Phosphate as an active ingredient. Clindagel was launched by Bausch in 2000.
Approval Date:
Clindagel was approved by FDA for market use on 27 November, 2000.
Active Ingredient:
Clindagel uses Clindamycin Phosphate as the active ingredient. Check out other Drugs and Companies using Clindamycin Phosphate ingredient
Treatment:
Clindagel is used for treating acne vulgaris.
Dosage:
Clindagel is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1% BASE | GEL | Prescription | TOPICAL |